Pharma 2020: From vision to decision
December 06, 2012
The traditional pharmaceutical industry business model has come under extraordinary pressure in recent years. Many agree it will be challenged both economically and operationally to act quickly enough to produce the types of innovative treatments demanded by global markets. Major scientific and technological advances, along with increasing global demand for medicines will help drive much of pharma's fortune into the next decade and beyond. But if the industry is to prosper, companies will need to embrace and pursue a different path.
Many of the conditions that will determine what happens in 2020 are already in place. Most of the products to be launched are already in the pipeline; development processes are similar to those used over the past 10 years; a demanding commercial environment looks set to continue; and the prevailing management culture remains that of the late twentieth century. A more flexible and adaptive model must be adopted.
PwC’s newest report Pharma 2020: From vision to decision discusses the challenges facing the industry at this critical juncture in time and what companies must do to succeed over the next decade and beyond.
Moderator:
Ben Comer
Senior Editor
Pharmaceutical Executive
Speakers:
Michael Swanick
Global Pharmaceuticals and Life Sciences Industry Leader
PwC
Steve Arlington
Global Pharmaceuticals and Life Sciences Advisory Services Leader
PwC
Recording details:
To listen to the recording of this webcast, please use link:
https://event.on24.com/eventRegistration/EventLobbyServlet?target=registration.jsp&
eventid=547229&sessionid=1&key=7D6DC5F8BF2D00BE0DB56C83C46E078E&
sourcepage=register
|
Medical Device Tax Technical Hot Topics webcast
23 August 2012
Successfully addressing the operational and systems implementation requirements of the Federal Medical Device Excise Tax (MDET)
Please join PwC for a complimentary Pharmaceutical and Life Sciences Tax Technical Hot Topics webcast: Successfully addressing the operational and systems requirements of the Federal Medical Device Excise Tax on Thursday, 23 August, 2012 from 11:00 AM - 12:00 PM (US EST).
The webcast will be hosted by Michael Swanick, PwC Global Pharmaceutical and Life Sciences Tax Leader. The session will be led by Advisory Services principal Carlos Moreira, managing director John Moran and Tax director Fred Gordon.
Effective January 1, 2013, manufacturers and importers of most medical devices will be subject to a 2.3% federal excise tax on sales of products made in the US. By some estimates the cost of this tax will be as much as $100M-$200M per year for larger organizations. To comply with the requirements, a fully functional automated compliance system must be designed, built, tested and deployed by January 2013. During the webcast, PwC tax and consulting professionals will be presenting an update on the key considerations involved in developing and implementing the operational and systems requirements to meet the filing deadline. The session will include case study examples to highlight how companies are meeting the data and operational challenges of building an effective system to support the tax reporting provisions.
Agenda:
- Overview of PwC MDET solution approach
- Technology challenges and solutions
- Process change considerations
- Questions and answers session
Recording details:
To listen to the recording of this webcast, please use link:
http://event.on24.com/eventRegistration/prereg/register.jsp?eventid=502226&sessionid=1&key=2BC6738F353A67716C47A61A4C0723B4
|
Pharma / Life Sciences Tax Technical Hot Topics Webcast
22 March 2012
Impact of US Tax Reform Proposals on the Pharmaceutical and Life Sciences Industry
Please join PwC for a complimentary Pharma / Life Sciences Tax Technical Hot Topics webcast: "The Impact of US Tax Reform Proposals on the Pharmaceutical and Life Sciences Industry" on Thursday, March 22, 2012 at 12 noon EDT.
The webcast will be hosted by Michael Swanick, Global Pharmaceuticals and Life Sciences Tax Leader. The speakers for this event will be WNTS Legislative and Regulatory Services Group Principal, Don Longano and WNTS International Tax Service Principal, Alan Fischl.
President Obama recently called on Congress to impose a minimum tax on overseas profits as part of an Administration framework for business tax reform and also has proposed that Congress enact a tax on "excess returns" from foreign intangible income that was included in his FY 2013 budget. While President Obama outlines his tax policy goals, the House and Senate tax committees are expected to focus this year primarily on laying a foundation for a future reform of U.S. tax laws by continuing to hold hearings on specific business and individual tax issues. Interested parties also are expected to continue to offer comments on the international tax reform discussion draft issued by Ways and Means Chairman, Dave Camp (R-MI), last October as well as other territorial tax proposals being proposed in Congress.
During this webcast, PwC tax professionals will discuss the key considerations related to the potential impact of these proposals on companies in the pharmaceutical and life sciences industry, and will provide insights on the prospects for significant changes in international tax policies.
Who should participate:
Tax VPs/Directors and their tax teams, CFOs, controllers, COOs, finance directors in pharmaceutical, medical device and biotechnology companies. Recommended CPE: application of 1 CPE taxation credit is in place.
Webcast Registration and Login To enter the webcast, please log on to the following URL 15 minutes prior to the scheduled start time.
http://event.on24.com/eventRegistration/prereg/register.jsp?eventid=410892&sessionid=1&key=4ADA8701E645CC725B3DD47AC1CD87B9
Audio Only: If you are unable to access the webcast audio on your PC, you can access the audio via telephone. Alternatively, if you are connected to the webcast via your PC, but are having trouble with the audio, use the "Non-Streaming" option by following the webcast link above to see the slides while you listen on the phone. Note: Listen-only participants are NOT eligible for CPE credit.
Dial-In Numbers (listen only):
United States: (866) 219 5631
International: (703) 639 1122
Conference ID: 1570550
NOTE: Please make sure you can access the webcast in advance. If for any reason you cannot open the link/presentation, please contact Marina Bello Valcarce at marina.bello.valcarce@uk.pwc.com or Kathleen Un at kathleen.un@us.pwc.com.
|
Medical Device Tax Technical Hot Topics webcast
24 January 2012
Will you be ready? Meeting the operational and systems challenges of the Federal Medical Device Excise Tax
Please join PwC for a complimentary Pharmaceutical and Life Sciences Tax Technical Hot Topics webcast: Will you be ready? Meeting the operational and systems challenges of the Federal Medical Device Excise Tax on Tuesday, 24 January, 2012 from 12:00 PM - 1:00 PM (US EST).
The webcast will be hosted by Michael Swanick, Global Pharmaceutical and Life Sciences Tax Leader.
Effective January 1, 2013, manufacturers and importers of most medical devices will be subject to a 2.3% federal excise tax on sales of products made in the US. By some estimates the cost of this tax will be as much as $100M-$200M per year for larger organizations. The tax will likely be treated similar to other federal manufacturer’s excise taxes wherein companies can decide to separately state the tax on customer invoices (indirect tax), absorb the tax into operating margins or factor the tax into product cost.
To comply with the requirements, a fully functional automated compliance system must be designed, built, tested and deployed by January 2013. During this webcast, PwC tax and consulting professionals will discuss the key considerations involved in developing and implementing the operational and systems requirements (i.e., understanding of product flow, transaction terms and conditions, information systems environment and other relevant information) to meet the filing deadline.
In addition, presenters will provide an overview of the medical device excise tax regulations (anticipated to be released by the date of the webcast). Potential issues that could be addressed by such guidance include:
- Classification of a "medical device" as being subject to the tax (including statutory exclusions and exemptions)
- Liability for, and collection of, the tax
- Calculation of sales price (including treatment of industry deductions, chargebacks and/or rebates)
- Procedural and registration related requirements
Who should participate?
Tax VPs/Directors and their tax teams, CFOs, controllers, COOs, finance directors, and senior supply chain executives in pharmaceutical, medical device and biotechnology companies.
Recommended CPE: application of 1 CPE taxation credit is in place.
Webcast Registration and Login
To enter the webcast, please log on to the following URL 15 minutes prior to the scheduled start time to make sure you can access the webcast in advance.
http://event.on24.com/r.htm?e=385919&s=1&k=5C170276E2F4797C4A7C9DCF8897735E Please note that CPE credit can only be given to individuals who remain logged into the live webcast and respond to the polling questions provided during the webcast.If you are viewing this webcast in a group, everyone in the group can receive CPE credit.
Audio Only:
If you are unable to access the webcast audio on your PC, you can access the audio via telephone. Alternatively, if you are connected to the webcast via your PC, but are having trouble with the audio, use the "Non-Streaming" option by following the webcast link above to see the slides while you listen on the phone. Note: Listen-only participants are NOT eligible for CPE credit.
Dial-In Numbers:
United States: (866) 206 7202
International: +1 (703) 639 1112
Conference ID: 1560968
For more information or if you cannot open the link/presentation, please contact Marina Bello Valcarce at marina.bello.valcarce@uk.pwc.com or Kathleen Un at kathleen.un@us.pwc.com.
Plain-English Accounting is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of continuing professional education on the National Registry of CPE Sponsors. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be addressed to the National Registry of CPE Sponsors, 150 Fourth Avenue North, Suite 700, Nashville, TN, 37219-2417. Web site: www.nasba.org
|
Thursday, 19 May, 2011
Pharma and Life Sciences Tax Webcast
Please register for a complimentary PricewaterhouseCoopers' Pharmaceutical and Life Sciences Tax Technical Hot Topics webcast on Thursday 19 May, 2011 from 12:00 PM - 1:30 PM (US EST). The webcast will be hosted by Michael Swanick, Global Pharmaceutical and Life Sciences Tax Leader and will cover the following topics:
-
Selected issues facing Pharmaceutical and Life Science companies in creating, developing and exploiting intellectual property within the United States and abroad
Today, companies face uncertainty and challenges in developing their intellectual property strategy. Pharmaceutical and Life Science companies create vast quantities of high-value intellectual property. As this intellectual property is created and exploited there are a multitude of issues to consider. This area has proven to be a point of contention between taxpayers and the IRS. Issues to be discussed will include the heightened focus on transfer pricing and intellectual property migration by U.S. regulatory authorities, U.S. legislative bodies, the Obama Administration, and the OECD.
-
Legislative landscape facing Pharmaceutical and Life Science companies.
As corporate tax reform is discussed in Washington, DC, companies need to understand the implications such reform proposals would have on their business. Issues to be discussed will include the various tax reform proposals, potential business and tax reporting impacts for companies and various revenue raising provisions.
-
Other Industry Issues
Much of the recent tax legislation has significantly impacted the Pharmaceutical & Life Science Industry, mostly notably the Patient Protection and Affordable Care Act. This discussion will briefly highlight other issues affecting Pharmaceutical and Life Science companies including the medical device excise tax, annual fee on branded prescription pharmaceuticals and Puerto Rico excise tax.
Who should participate?
Tax VPs/Directors and their tax teams, CFOs, controllers, COOs, finance directors, and senior supply chain executives in pharmaceutical, medical device and biotechnology companies.
Recommended CPE: application of 1.5 CPE taxation credit is in place.
Webcast Registration and Login
To enter the webcast, please log on to the following URL 15 minutes prior to the scheduled start time.
http://event.on24.com/r.htm?e=302203&s=1&k=99E6C381094E84318D8C2B9C108E179C
NOTE: Please make sure you can access the webcast in advance. If for any reason you cannot open the link/presentation, please contact Marina Bello Valcarce at marina.bello.valcarce@uk.pwc.com or Kathleen Un at kathleen.un@us.pwc.com.
Plain-English Accounting is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of continuing professional education on the National Registry of CPE Sponsors. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be addressed to the National Registry of CPE Sponsors, 150 Fourth Avenue North, Suite 700, Nashville, TN, 37219-2417. Web site: www.nasba.org
|
26 April, 2011
Pharma 2020: Supplying the future
In this Webcast, a panel of specialists will discuss significant changes the pharmaceutical supply chain is expected to undergo in the coming years and then explore potential scenarios for how pharmaceutical companies might restructure their supply chain strategy and operating models, depending on their unique product portfolio and channel strategy. The discussion will focus on the risks, opportunities and challenges in each of the four future supply chain models -- virtual manufacturer, service innovator, a mass market manufacturer or a profit center – identified by PwC in its groundbreaking report Pharma 2020: Supplying the Future: Which path will you take?
|
September 16, 2010
New Excise Taxes on Pharmaceutical and Medical Device Manufacturers and; New Irish Transfer Pricing Regulations for Global Pharmaceutical, Medical Device and Biotechnology Companies
Please register for a complimentary PwC's Pharmaceutical and Life Sciences Tax Technical Hot Topics webcast on Thursday 16 September, 2010 from 12:00 PM - 1:00 PM (US EST). The webcast was hosted by Michael Swanick, Global Pharmaceutical and Life Sciences Tax Leader and will cover the following two topics:
http://event.on24.com/eventRegistration/prereg/register.jsp?eventid=264994&sessionid=1&key=C09E88B87C7CA9E5BA8F0E14C2457874
|
May 25, 2010
Deciphering the initial Treasury guidance on Section 48D therapeutic discovery project credit,
On this webcast, a panel of PwC Life Science and Pharmaceutical industry specialists, National Tax, Economics and Government Grant specialists, as well as invited government speakers, discussed and assessed anticipated guidance on how companies may qualify and apply for the Section 48D therapeutic discovery project credit (or a grant in lieu of the credit).
The Webcast provided an initial overview of the Treasury guidance, a discussion of the programme's eligibility and selection criteria, and how the credit/grant application process works.
|
15 October, 2009
US healthcare reform: A briefing on the major business and tax impacts affecting pharmaceutical, medical device and biotechnology companies
Webcasts - Previous webcasts 
|
8 July, 2009
US Tax Reform Proposals and the New Irish Intellectual Property Rules - Impact on Pharma, Life Sciences and Medical Device Companies
|
7 May, 2009
Podcast: Update on China's changing pharmaceutical landscape
Michael Keech, director, Pharmaceutical and Life Sciences Advisory Services Group, being interviewed by Genetic Engineering News on the changing pharmaceutical landscape in China.
|
|
10 February, 2009
Audioconference: Sales & Marketing Disclosure Requirements
Update on Sales and Marketing Disclosure Requirements for Drug, Device and Biotech Companies
For more information, click here
|
|
27 January, 2009
IFRS conversion: Understanding the key tax issues for Pharmaceuticals, Life Sciences and Medical Devices companies
Key discussion topics include planning considerations and tax accounting method changes.
Archive
|
19 December, 2008
President-Elect Obama's Plans for Healthcare and Tax
Access the presentation - Adobe Acrobat file (201kb) |
|
